Sci-dip

A major problem in the rare disease sector is the lack of bridges between research and the clinic.

While rare diseases truly are rare, their occurrence unfortunately isn't. Indeed, 1 out of 10 Americans suffer from one of 7000 different rare diseases. What it means is that it is extremely difficult for a physician to be expert in all of these 7000 diseases, and this leads to different problems for patients:

1) MEDICAL WANDERING

Patients with rare disease often find themselves jumping many times from one MD to another before discovering what they have. This of course delay treatment and can alter response to treatment.

2) LIMITED INFORMATION ON THEIR CONDITION

Beyond diagnosis, MDs have little (or at least incomplete) knowledge on the given disease. They are rarely (pun intended) up to date with the latest research in the field.

3) NO PERSONALIZED TREATMENT

Because MDs are rarely experts in one specific rare disease (not a viable option), they are not able to provide personalized / precision medicine.

Sci-dip bridges the gap between research and the clinic. Indeed we position ourselves as a scientific partner as we provide more research-based information on the patient's condition.

We have a network of health experts (mainly PhDs) with cutting-edge knowledge on a wide range of rare diseases (we cover to date 2500 different illnesses and our expertise is growing at a fast pace). Each expert has worked for decades on very specific aspects of one single rare disease. They are thus best positioned to complement the MDs work in the clinic and to bring to the patient valuable information on their symptoms, their prognosis, and the general evolution of their condition.

We further capitalize on every data entry and every metric to transform the fundamental research data gathered by our health experts into predictive analyses and POVs.

All patients suffering from a rare disease can benefit from the Sci-dip solution. We have prioritized rare diseases associated with chronic resistant pain but our solution can quickly adapt to the need of almost any rare disease, as long as it is studied in a research lab. If the lab or one of its researchers is not already part of our network, we are in capacity to establish connection in a couple of days.

This allows patients to address all their concerns regarding the evolution of their symptoms and to obtain the latest information on potential upcoming treatments (whether in preclinic or already in clinical trials).

My co-founder Alexandre Mendes (PhD) and myself (also PhD) are both at the intersection between academia and the industry, with a strong desire to translate fundamental discoveries from the former into concrete solutions developed by the latter. 

I personally worked (as a psychologist) in the clinic for a couple of years with a young patient suffering from a rare ataxia, a brain disease called "Chiari Malformation". As much as I was determined to help him, I felt powerless and ignorant when it came to his suffering. This is why I decided to pursue a PhD in neuroscience, with the aim to better understand the neurobiological mechanisms that underpinned the symptoms I had witnessed in the clinic.

One of my closest friends was later diagnosed with Central Pain Syndrome, a rare disorder characterized by chronic severe (and completely debilitating) pain. That is when I realized that the occurrence of rare diseases is unfortunately not rare. I have been since very implicated in rare disease associations in France, namely "Fondation Maladies Rares" and I strongly believe that an important part of the solution can come from building channels to share fundamental research advances with patients and MDs in the rare disease sector.

Accelerate the impact
Expand to the US